Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Transplantation of Bone Marrow Stem Cells Stimulated by Proteins Scaffold to Heal Defects Articular Cartilage of the Knee

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2013 by University of Marseille
Sponsor:
Information provided by (Responsible Party):
Michel Assor, MD, University of Marseille
ClinicalTrials.gov Identifier:
NCT01159899
First received: July 6, 2010
Last updated: January 7, 2013
Last verified: January 2013

July 6, 2010
January 7, 2013
July 2010
December 2014   (final data collection date for primary outcome measure)
  • IKS, International Knee Score [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    measure assess of the knee function
  • IKS, International Knee Score [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    measure assess of the knee function
Same as current
Complete list of historical versions of study NCT01159899 on ClinicalTrials.gov Archive Site
  • KOOS, Knee Injury and Osteoarthritis Outcome Score [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    measure assess of the knee function and quality of the new cartilage
  • KOOS, Knee Injury and Osteoarthritis Outcome Score [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    measure assess of the knee function and quality of the new cartilage
  • ICRS, International Cartilage Research Society [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    measure assess of the knee function and quality of the new cartilage
  • ICRS, International Cartilage Research Society [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    measure assess of the knee function and quality of the new cartilage
Not Provided
Not Provided
 
Transplantation of Bone Marrow Stem Cells Stimulated by Proteins Scaffold to Heal Defects Articular Cartilage of the Knee
Pilot Study of A One-Step Procedure for the Use of Autologous Bone Marrow Mesenchymal Stem Cells Stimulated by Proteins Scaffold to Heal Under Arthroscopy Full-Thickness Defects Articular Cartilage and Osteoarthrosis of the Knee.

The purpose of this pilot study is to investigate the efficacy and safety of autologous transplantation, under arthroscopy, of Bone Marrow Mesenchymal stem cells, using, with a cell separator, a fresh non-culture expanded Autologous Bone Marrow derived Mesenchymal Stem, mixed and activated with proteins scaffold in patient with Knee cartilage defects and osteoarthritis. Based on extensive preclinical investigations, the technology of using freshly isolated bone marrow mononuclear cells mixed with proteins seems safe and most effective for a one-step correction of cartilage defect and restoration of the osteochondral complex, because the same mixture can generate cartilage in the vasculature-free knee joint, and bone in the environment of bone defects.

Before the implantation of the mesenchymal stem cells, a knee arthroscopy procedure is made for the debridement of the meniscal and cartilage lesions, with microperforation and abrasion, preparation of the osteochondral defect to receive the transplantation, patellar lateral release if necessary.

Then, the investigators use a fresh non-culture expanded autologous bone marrow derived mesenchymal mononuclear stem cells, stimulated with a protein matrix and mixed in a collagen hydroxyapatite scaffold. This cellular paste is transplanted in the prepared defect, under arthroscopy, with injection of platelet rich plasma.

Interventional
Phase 0
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Osteoarthritis
  • Knee Osteoarthritis
  • Osteochondritis Dissecans
  • Osteonecrosis
Procedure: Transplantation of Bone Marrow Stem Cells Activated in Knee Arthrosis
Transplantation of Activated Bone Marrow Stem Cells in Knee Arthrosis, under arthroscopy, in one-step procedure
Other Names:
  • mesenchymal stem cells
  • Knee Arthrosis
  • Knee osteochondral defect
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
December 2014
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Active patients (30 to 75 years)
  • A localized osteochondral defect of both condyle and/or tibia grade 4 (ICRS classification)
  • with cartilage on the tibial surface no more than grade 3-4, of size < 3-4 cm2, with 3/4 of meniscus present.
  • Stable knee ; previous ligament reconstruction, if stable
  • A defect that is 1 - 4 cm2 or more, up to 6 cm2, located on the femoral condyle and /or less of 4 cm2 for tibial plate, and IKS score <75.
  • Kissing lesions admitted
  • Ability to understand and willingness to sign consent form

Exclusion Criteria:

  • Patients younger than 30 years and older than 75 years
  • Diffuse and advanced articular cartilage degeneration of the joint
  • Axial malalignment, meniscal pathology, and ligamentous instability are relative contraindications that have to be dealt with primarily either concomitantly or before the transplantation during 1 of the 2 stages of the procedure. Refusal of the patient to address these conditions in presence of a cartilage lesion is a criterion for exclusion from the study, to avoid the impact of these knee pathologies on the final results
  • Existing infection in or around the joint & lesions of infectious or oncologic etiology.
  • Debilitated patients.
  • Immunocompromised patients.
  • Patients with autoimmune disorders & systemic inflammatory disease.
  • Preoperative poor neurological or vascular status of the affected limb.
  • Specific contraindications include the use of tobacco and medications that may impair cell proliferation, such as NSAIDs and immunosuppressive drugs. Patients must be nicotine-free (stop smoking) prior to the procedure, as studies have shown that the oxidative effect of smoking impairs cell function and subsequent healing.
Both
30 Years to 75 Years
No
Contact: Michel Assor, MD 0033611950518 / 0033609505060 michel.assor@free.fr
Contact: Shimon Slavin, Pr slavin@CTCIcenter.com
France
 
NCT01159899
MSC- AS3
Yes
Michel Assor, MD, University of Marseille
Michel Assor, MD
Not Provided
Principal Investigator: Michel Assor, MD Knee and Lower Limb Institute, Marseille, France
Study Director: Shimon Slavin, MD The International Center for Cell Therapy & Cancer (ICTC), Tel Aviv, Israel
University of Marseille
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP